The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

Cancer Cell

Volumn 19, Issue 2, 2011, Pages 273-282

  Knappskog, Stian ^a,b   Bjørnslett, Merete ^c,d   Myklebust, Line M ^a   Huijts, Petra E A ^e   Vreeswijk, Maaike P ^e   Edvardsen, Hege ^c   Guo, Yongli ^f   Zhang, Xuemei ^f   Yang, Ming ^f   Ylisaukko oja, Sanna K ^g   Alhopuro, Pia ^g   Arola, Johanna ^g   Tollenaar, Rob A E M ^e   van Asperen, Christi J ^e   Seynaeve, Caroline ^h   Staalesen, Vidar ^a,b   Chrisanthar, Ranjan ^a,b   Løkkevik, Erik ^c   Salvesen, Helga B ^a,b   Evans, D Gareth ⁱ   Newman, William G ⁱ   Lin, Dongxin ^f   Aaltonen, Lauri A ^g   Børresen Dale, Anne Lise ^c,d   Tell, Grethe S ^a   Stoltenberg, Camilla ^j   Romundstad, Pål ^k   Hveem, Kristian ^k   Lillehaug, Johan R ^a   Vatten, Lars ^k   Devilee, Peter ^e   Dørum, Anne ^c,d   Lønning, Per E ^a,b   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CANCER HOSPITAL   (China)

^g UNIVERSITY OF HELSINKI   (Finland)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^k NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR SP1;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79751471610     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.12.019     Document Type: Article

References (39)

1. Hereditary breast and ovarian cancer syndrome. Gynecol. Oncol. 2009, 113:6-11. ACOG.
2. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., Gilbert M., Hamann U., Scott R.J. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol. Oncol. 2009, 113:109-114.
3. Atwal G.S., Bond G.L., Metsuyanim S., Papa M., Friedman E., Distelman-Menachem T., Ben Asher E., Lancet D., Ross D.A., Sninsky J., et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc. Natl. Acad. Sci. USA 2007, 104:4524-4529.
4. Bartel F., Meye A., Wurl P., Kappler M., Bache M., Lautenschlager C., Grunbaum U., Schmidt H., Taubert H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 2001, 95:168-175.
5. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
6. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., Bartel F., Taubert H., Wuerl P., Hait W., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006, 66:5104-5110.
7. Buscemi G., Savio C., Zannini L., Micciche F., Masnada D., Nakanishi M., Tauchi H., Komatsu K., Mizutani S., Khanna K., et al. Chk2 activation dependence on Nbs1 after DNA damage. Mol. Cell. Biol. 2001, 21:5214-5222.
8. Buscemi G., Perego P., Carenini N., Nakanishi M., Chessa L., Chen J., Khanna K., Delia D. Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 2004, 23:7691-7700.
9. Campbell I.G., Eccles D.M., Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006, 240:195-197.
10. Chrisanthar R., Knappskog S., Lokkevik E., Anker G., Ostenstad B., Lundgren S., Berge E.O., Risberg T., Mjaaland I., Maehle L., et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS ONE 2008, 3:e3062.
11. Copson E.R., White H.E., Blaydes J.P., Robinson D.O., Johnson P.W., Eccles D.M. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 2006, 6:80.
12. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
13. Economopoulos K.P., Sergentanis T.N. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res. Treat. 2010, 120:211-216.
14. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
15. Ellis N.A., Huo D., Yildiz O., Worrillow L.J., Banerjee M., Le Beau M.M., Larson R.A., Allan J.M., Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008, 112:458-459.
16. Fang Y., Kong B., Yang Q., Ma D., Qu X. MDM2 309 polymorphism is associated with missed abortion. Hum. Reprod. 2009, 24:1346-1349.
17. Francisco, G., Menezes, P.R., Eluf-Neto, J., and Chammas, R. (2010). Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int. J. Cancer DOI: 10.1002/ijc.25710.
18. Galic V., Willner J., Wollan M., Garg R., Garcia R., Goff B.A., Gray H.J., Swisher E.M. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007, 46:239-247.
19. Hu Z., Jin G., Wang L., Chen F., Wang X., Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2717-2723.
20. Kang S., Wang D.J., Li W.S., Wang N., Zhou R.M., Sun D.L., Duan Y.N., Li S.Z., Li X.F., Li Y. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int. J. Gynecol. Cancer 2009, 19:572-577.
21. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 375:691-694.
22. Meyn M.S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 1999, 55:289-304.
23. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
24. Nechushtan H., Hamburger T., Mendelson S., Kadouri L., Sharon N., Pikarsky E., Peretz T. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer 2009, 9:60.
25. Nunobiki O., Ueda M., Yamamoto M., Toji E., Sato N., Izuma S., Okamoto Y., Torii K., Noda S. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum. Cell 2009, 22:101-106.
26. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83.
27. Paulin F.E., O'Neill M., McGregor G., Cassidy A., Ashfield A., Ali C.W., Munro A.J., Baker L., Purdie C.A., Lane D.P., Thompson A.M. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 2008, 8:281.
28. Peltonen L., Jalanko A., Varilo T. Molecular genetics of the Finnish disease heritage. Hum. Mol. Genet. 1999, 8:1913-1923.
29. Post S.M., Quintas-Cardama A., Pant V., Iwakuma T., Hamir A., Jackson J.G., Maccio D.R., Bond G.L., Johnson D.G., Levine A.J., Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010, 18:220-230.
30. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
31. Sandelin A., Alkema W., Engstrom P., Wasserman W.W., Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004, 32:D91-D94.
32. Schmidt M.K., Reincke S., Broeks A., Braaf L.M., Hogervorst F.B., Tollenaar R.A., Johnson N., Fletcher O., Peto J., Tommiska J., et al. D. MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007, 67:9584-9590.
33. Smirnov D.A., Cheung V.G. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am. J. Hum. Genet. 2008, 83:243-253.
34. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
35. Ueda M., Yamamoto M., Nunobiki O., Toji E., Sato N., Izuma S., Okamoto Y., Torii K., Noda S. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum. Cell 2009, 22:49-54.
36. Varon R., Reis A., Henze G., von Einsiedel H.G., Sperling K., Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 2001, 61:3570-3572.
37. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698.
38. Yang Q., Flanders W.D., Moonesinghe R., Ioannidis J.P., Guessous I., Khoury M.J. Using lifetime risk estimates in personal genomic profiles: estimation of uncertainty. Am. J. Hum. Genet. 2009, 85:786-800.
39. Yarden R.I., Friedman E., Metsuyanim S., Olender T., Ben-Asher E., Papa M.Z. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 2008, 111:497-504.